Incannex Healthcare
- Country
- 🇦🇺Australia
- Ownership
- -
- Employees
- 10
- Market Cap
- $34.7M
- Introduction
Incannex Healthcare, Inc. is a biotech company, which engages in developing cannabinoid and psychedelic compound medicines. It focuses on the research and development for medicinal cannabis pharmaceutical products and psychedelic medicine therapies for treatment of a range of indications. The company was founded on July 5, 2023 and is headquartered in Norwest, Australia.
Clinical Trials
5
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA
- Conditions
- Obstructive Sleep Apnea
- Interventions
- Drug: IHL-42X High DoseDrug: PlaceboDrug: IHL-42X (Optimal Dose)Drug: IHL-42X Low Dose
- First Posted Date
- 2023-11-24
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Incannex Healthcare Ltd
- Target Recruit Count
- 560
- Registration Number
- NCT06146101
- Locations
- 🇺🇸
Exalt Clinical Research, Chula Vista, California, United States
🇺🇸CenExel CNS- Los Alamitos, Long Beach, California, United States
🇺🇸Pacific Clinical Research Medical Group, Upland, California, United States
Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2023-07-12
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Incannex Healthcare Ltd
- Target Recruit Count
- 20
- Registration Number
- NCT05942911
- Locations
- 🇦🇺
Paratus Clinical (Woden Dermatology), Phillip, Australian Capital Territory, Australia
🇦🇺Genesis Research Services, Broadmeadow, New South Wales, Australia
🇦🇺Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
Bioavailability, Bioequivalence and Tolerability of IHL-42X Compared to the Reference Drugs
- Conditions
- Obstructive Sleep Apnea
- Interventions
- First Posted Date
- 2023-05-12
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Incannex Healthcare Ltd
- Target Recruit Count
- 125
- Registration Number
- NCT05857384
- Locations
- 🇦🇺
CMAX, Adelaide, South Australia, Australia
🇦🇺Nucleus Network Pty Ltd, Melbourne, Victoria, Australia
🇦🇺Nucleus Network Pty Ltd [Commercial Road], Melbourne, Victoria, Australia
News
Incannex Eliminates 347 Million Share Dilution Ahead of Pivotal Sleep Apnea Drug Trial Results
Incannex Healthcare has entered a binding agreement to cancel 172 million Series A Warrants for $12.2 million, eliminating up to 347.2 million shares from potential dilution when combined with earlier cancellations.